CLARITY Study

Cross-source consensus on CLARITY Study from 1 sources and 4 claims.

1 sources · 4 claims

Evidence quality

CLARITY is a national Australian multicentre observational cohort study of infections after CAR-T and bispecific antibody therapy in adults with lymphoproliferative neoplasms. — Longitudinal real-world surveillance of infection outcomes in CAR-T and bispecific therapy recipients: the CLARITY study protocol
The study is conducted across six adult Australian centres that provide standard-of-care CAR-T therapy for lymphoma. — Longitudinal real-world surveillance of infection outcomes in CAR-T and bispecific therapy recipients: the CLARITY study protocol
CLARITY uses retrospective or routinely collected health data under a waiver of consent because it is considered low risk. — Longitudinal real-world surveillance of infection outcomes in CAR-T and bispecific therapy recipients: the CLARITY study protocol
The study protocol follows the STROBE checklist for observational cohort studies. — Longitudinal real-world surveillance of infection outcomes in CAR-T and bispecific therapy recipients: the CLARITY study protocol